Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Crinetics Pharmaceuticals Inc (NQ: CRNX ) 56.69 +0.73 (+1.30%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 357,010 Open 56.50 Bid (Size) 54.24 (1) Ask (Size) 58.41 (1) Prev. Close 55.96 Today's Range 56.19 - 57.81 52wk Range 25.75 - 60.04 Shares Outstanding 54,026,103 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024 October 16, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 10, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Performance YTD +60.19% +60.19% 1 Month +7.43% +7.43% 3 Month +15.36% +15.36% 6 Month +21.91% +21.91% 1 Year +84.66% +84.66% More News Read More Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock October 08, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire What Analysts Are Saying About Crinetics Pharmaceuticals Stock September 27, 2024 Via Benzinga A Closer Look at 11 Analyst Recommendations For Crinetics Pharmaceuticals August 09, 2024 Via Benzinga Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock October 08, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly September 26, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 10, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Forecasting The Future: 11 Analyst Projections For Crinetics Pharmaceuticals June 28, 2024 Via Benzinga 17 Analysts Have This To Say About Crinetics Pharmaceuticals June 04, 2024 Via Benzinga Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences August 29, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 12, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire CRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024 August 08, 2024 Via InvestorPlace Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update August 08, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges August 08, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024 July 18, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details July 14, 2024 Via Benzinga 10 Health Care Stocks With Whale Alerts In Today's Session July 01, 2024 Via Benzinga 7 Biotech Stocks to Boost Your Portfolio to Peak Health June 26, 2024 Via InvestorPlace EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner June 18, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 10, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Nvidia To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday June 04, 2024 Via Benzinga Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS) June 03, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly June 03, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs May 30, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
